Document Detail

Encapsulated glucagon-like Peptide-1-producing mesenchymal stem cells have a beneficial effect on failing pig hearts.
MedLine Citation:
PMID:  23197668     Owner:  NLM     Status:  In-Data-Review    
Stem cell therapy is an exciting and emerging treatment option to promote post-myocardial infarction (post-MI) healing; however, cell retention and efficacy in the heart remain problematic. Glucagon-like peptide-1 (GLP-1) is an incretin hormone with cardioprotective properties but a short half-life in vivo. The effects of prolonged GLP-1 delivery from stromal cells post-MI were evaluated in a porcine model. Human mesenchymal stem cells immortalized and engineered to produce a GLP-1 fusion protein were encapsulated in alginate (bead-GLP-1 MSC) and delivered to coronary artery branches. Control groups were cell-free beads and beads containing unmodified MSCs (bead-MSC), n = 4-5 per group. Echocardiography confirmed left ventricular (LV) dysfunction at time of delivery in all groups. Four weeks after intervention, only the bead-GLP-1 MSC group demonstrated LV function improvement toward baseline and showed decreased infarction area compared with controls. Histological analysis showed reduced inflammation and a trend toward reduced apoptosis in the infarct zone. Increased collagen but fewer myofibroblasts were observed in infarcts of the bead-GLP-1 MSC and bead-MSC groups, and significantly more vessels per mm(2) were noted in the infarct of the bead-GLP-1 MSC group. No differences were observed in myocyte cross-sectional area between groups. Post-MI delivery of GLP-1 encapsulated genetically modified MSCs provided a prolonged supply of GLP-1 and paracrine stem cell factors, which improved LV function and reduced epicardial infarct size. This was associated with increased angiogenesis and an altered remodeling response. Combined benefits of paracrine stem cell factors and GLP-1 were superior to those of stem cells alone. These results suggest that encapsulated genetically modified MSCs would be beneficial for recovery following MI.
Elizabeth J Wright; Kelly A Farrell; Nadim Malik; Moustapha Kassem; Andrew L Lewis; Christine Wallrapp; Cathy M Holt
Related Documents :
9527228 - Obstructive rhabdomyoma and univentricular physiology: a rare combination.
15889208 - Ascites and other extracardiac manifestations associated with right atrial myxoma: a ca...
3970298 - Differences between nonfamilial and familial cardiac myxoma.
18583288 - Surgical resection of left atrial myxoma presenting with acute multiple hemorrhagic cer...
16029378 - Usefulness of seismocardiography for the diagnosis of ischemia in patients with coronar...
19010528 - The effect of injected rgd modified alginate on angiogenesis and left ventricular funct...
Publication Detail:
Type:  Journal Article     Date:  2012-09-27
Journal Detail:
Title:  Stem cells translational medicine     Volume:  1     ISSN:  2157-6564     ISO Abbreviation:  Stem Cells Transl Med     Publication Date:  2012 Oct 
Date Detail:
Created Date:  2012-11-30     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101578022     Medline TA:  Stem Cells Transl Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  759-69     Citation Subset:  IM    
Institute for Cardiovascular Science, University of Manchester, Manchester, United Kingdom.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Development and characterization of a clinically compliant xeno-free culture medium in good manufact...
Next Document:  The Proposed Changes for DSM-5 for SLD and ADHD: International Perspectives--Australia, Germany, Gre...